434 related articles for article (PubMed ID: 30122651)
21. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
[TBL] [Abstract][Full Text] [Related]
22. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
23. Eosinophilic Otitis Media Treated with Anti-IgE Monoclonal Antibodies and A Bone Conduction Implant.
Han YE; Kang YS; Cho Y; Park MK
J Int Adv Otol; 2018 Apr; 14(1):144-147. PubMed ID: 29764789
[TBL] [Abstract][Full Text] [Related]
24. IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma.
Shimizu H; Hayashi M; Kato H; Nakagawa M; Imaizumi K; Okazawa M
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681869
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
[TBL] [Abstract][Full Text] [Related]
26. Role of IgE in eosinophilic otitis media.
Iino Y
Allergol Int; 2010 Sep; 59(3):233-238. PubMed ID: 20657163
[TBL] [Abstract][Full Text] [Related]
27. Periostin in middle ear mucosa according to eosinophilic otitis media severity: Middle ear pathology-based treatment.
Esu Y; Masuda M; Yoshida N
Auris Nasus Larynx; 2020 Aug; 47(4):527-535. PubMed ID: 32586742
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
[TBL] [Abstract][Full Text] [Related]
29. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
30. Eustachian tube function in patients with eosinophilic otitis media associated with bronchial asthma evaluated by sonotubometry.
Iino Y; Kakizaki K; Saruya S; Katano H; Komiya T; Kodera K; Ohta K
Arch Otolaryngol Head Neck Surg; 2006 Oct; 132(10):1109-14. PubMed ID: 17043260
[TBL] [Abstract][Full Text] [Related]
31. Treatment of eosinophilic otitis media with pegylated interferon-α 2a and 2b.
Neff BA; Voss SG; Carlson ML; O'Brien EK; Butterfield JH
Laryngoscope; 2017 May; 127(5):1208-1216. PubMed ID: 27667784
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
[TBL] [Abstract][Full Text] [Related]
33. Antigen-specific IgE in middle ear effusion of patients with eosinophilic otitis media.
Kanazawa H; Yoshida N; Shinnabe A; Iino Y
Ann Allergy Asthma Immunol; 2014 Jul; 113(1):88-92. PubMed ID: 24863399
[TBL] [Abstract][Full Text] [Related]
34. Role of Interleukin 5 Inhibition in the Treatment of Eosinophilic Otitis Media.
Breslin NK; Heindel NH; Haberman RS
OTO Open; 2021; 5(1):2473974X21991449. PubMed ID: 33598601
[TBL] [Abstract][Full Text] [Related]
35. Eosinophilic otitis media and comorbid asthma.
Seo Y; Nonaka M; Pawankar R
Curr Opin Allergy Clin Immunol; 2020 Feb; 20(1):9-13. PubMed ID: 31524656
[TBL] [Abstract][Full Text] [Related]
36. Mepolizumab and exacerbations of refractory eosinophilic asthma.
Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
[TBL] [Abstract][Full Text] [Related]
37. Intractable otitis media - Pathogenesis and treatment of Eosinophilic otitis media (EOM) and otitis media with Antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (OMAAV).
Yoshida N
Auris Nasus Larynx; 2023 Apr; 50(2):171-179. PubMed ID: 35934599
[TBL] [Abstract][Full Text] [Related]
38. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
[TBL] [Abstract][Full Text] [Related]
39. Dupilumab improves eosinophilic otitis media associated with eosinophilic chronic rhinosinusitis.
Nakashima D; Nakayama T; Minagawa S; Adachi T; Mitsuyama C; Shida Y; Nakajima T; Haruna SI; Matsuwaki Y
Allergol Int; 2023 Oct; 72(4):557-563. PubMed ID: 37061391
[TBL] [Abstract][Full Text] [Related]
40. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response.
Drick N; Seeliger B; Welte T; Fuge J; Suhling H
BMC Pulm Med; 2018 Jul; 18(1):119. PubMed ID: 30021546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
